One way analysis of variance (ANOVA) statistical test was used to compare the groups, and post hoc tests were used where there is significant selleck products difference to compare between and within groups. Results and discussion Animal grouping Rats were arranged into four treatment and one control group at the commencement of the study as shown in Table 1. Morbidity and mortality Morbidity, mortality and gross pathology results of sub-acute toxicity study in rats after repeated oral doses were presented

in this study. Weight changes during the study The animals treated with zinc-aluminium layered hydroxide nanocomposite intercalated and unintercalated with levodopa over 28 days showed no mortality. The food and water intake in both control and treatment groups were unaffected during the study period. No signs of toxicity, such as vomiting, diarrhoea, paralysis, convulsion, restless, irritation, bleeding and breathing difficulties were observed in any of the groups (Table 2). During the course of experiment, rats treated with high and low doses of nanocomposite showed a sustained weight gain similar to their counterpart in the vehicle control group. The weight gain was shown to be continuous over the study period; statistically, the difference in weight gain between day 0 and all other days in all the groups is significant (p < 0.05) (Figure 1).

However, body weight changes between weeks were found to Peptide 17 clinical trial be statistically significant (p < 0.05), meaning the weight gain in all group from day zero (0) is statistically significant compared to weight in

the subsequent weeks. The coefficient of the brain, liver, spleen, heart and kidney was presented in Table 3. It is the ratio of these organs to the whole body taken on the 28th day. There were no significant differences observed in the coefficients of these organs. Thus, 28 days of repeated doses of ZAL and ZA at 5 and 500 mg/kg, via oral route did not show any effect on these organs’ weight in XAV-939 ic50 relation to the whole body weight. This implies that orally administered ZAL from and ZA at 5 or 500 mg/kg respectively do not induce any obvious clinical toxicity or do they resulted in any animal demise. Table 2 Morbidity, mortality and gross pathology results of sub-acute toxicity study in rats after repeated oral doses Group Dose (mg/kg) body weight Toxicity sign t/n Mortality d/a Gross pathology l/nl ZALH 500 0/8 0/8 0/8 ZALL 5 0/8 0/8 0/8 ZAH 500 0/8 0/8 0/8 ZAL 5 0/8 0/8 0/8 VC 0 (vehicle) 0/8 0/8 0/8 Based on the doses used, no rats showed any clinical toxicity sign, no death was recorded, and no obvious gross pathology seen on the organs observed. Data are expressed as means ± SD, n = 8. t/n (toxic/normal), d/a (dead/alive), l/nl (lesion/no lesion). ZALH, zinc aluminium levodopa nanocomposite high dose; ZALL, zinc aluminium levodopa nanocomposite low dose; ZAH, zinc aluminium nanocomposite high dose; ZAL, zinc aluminium nanocomposite low dose; VC, vehicle control.